-+ 0.00%
-+ 0.00%
-+ 0.00%

Candel Therapeutics Presents New Biomarker Data From Its Phase 3 Clinical Study Of Aglatimagene Besadenovec

Benzinga·09/30/2026 12:08:37
Listen to the news

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2026.